Istradefilina mostrou perfil de segurança aceitável como terapia adjuvante da levodopa no tratamento da Doença de Parkinson

Referência

1. Abstract 482. Waters, C et al. A Pooled Analysis of Four Pivotal Randomized Controlled Trials of Istradefylline, an Adenosine A2A Receptor Antagonist: Efficacy as Adjunct to Levodopa in Parkinson’s Disease (PD) – 145th Annual Meeting American Neurological Association Presented virtually October 4–9, 2020